Complement Receptor 1: disease associations and therapeutic implications
1Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029, India.
Insights
Complement Receptor 1 (CR1) plays a vital role in autoimmune and inflammatory diseases. Understanding CR1
Area of Science:
- Immunology
- Molecular Biology
- Genetics
Background:
- Exaggerated complement activation contributes to autoimmune and inflammatory diseases.
- Complement Receptor 1 (CR1) is a key regulator of complement.
- CR1's role in disease pathogenesis is of significant interest.
Purpose of the Study:
- To provide a comprehensive review of Complement Receptor 1 (CR1).
- To elucidate CR1's structure, functions, and genetics.
- To explore CR1's association with diseases and its therapeutic potential.
Main Methods:
- Literature review of existing research on CR1.
- Analysis of studies on CR1 structure and function.
- Examination of genetic data and disease associations.
Main Results:
- CR1 exhibits diverse functions in regulating complement activation.
- Genetic variations in CR1 are linked to susceptibility to various diseases.
- CR1 is implicated in the pathophysiology of autoimmune and inflammatory conditions.
Conclusions:
- CR1 is a critical factor in the complement system's role in disease.
- Further research into CR1 offers diagnostic and therapeutic opportunities.
- CR1 modulation may represent a novel treatment strategy for related diseases.
Abstract:
Exaggerated complement activation is a key event in the pathogenesis of a range of autoimmune and inflammatory diseases. Complement Receptor 1 (CR1) has emerged as a molecule of immense interest in gaining insight to the susceptibility, pathophysiology, diagnosis, prognosis and therapy of such diseases. This review brings forth a composite view of the current understanding on the structure, functions, genetics, disease associations and therapeutic implications of CR1.
Related Concept Videos
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Pharmacogenomics: Identification of New Drug Targets
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Cardiomyopathy IV: Restrictive Cardiomyopathy
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Rheumatic Heart Disease I: Introduction


